Facebook icon DKA with SGLT2 Inhibitor Use Update | Diabetes Qualified

Subscribe to our monthly enews

Proudly supported by Diabetes NSW & ACT and Diabetes Queensland.

Background
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are oral medications that promote glucose excretion in the urine for the
treatment of type 2 diabetes. Note that SGLT2i are not approved for use in the management of type 1 diabetes in Australia or
New Zealand, although they are sometimes used off-label in this setting.

Click below for the full update.

ADS_DKA_SGLT2i_Alert_update_2020